Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Cyclophosphamide + Fludarabine
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cyclophosphamide Cytoxan CPM Chemotherapy - Alkylating 14 Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).
Fludarabine Fludara FAMP|Fludarabine phosphate Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT03019666 Phase I Allogeneic NAM NK cells Cyclophosphamide + Fludarabine Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL Recruiting
NCT02869217 Phase I Cyclophosphamide + Fludarabine TBI-1301 Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Recruiting
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting
NCT03233854 Phase I Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies Recruiting
NCT01701674 Phase I Cyclophosphamide + Fludarabine Ipilimumab Aldesleukin Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Active, not recruiting
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Recruiting
NCT02153580 Phase I Etoposide Cyclophosphamide + Fludarabine Bendamustine Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia Recruiting
NCT02287311 Phase I LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) Recruiting
NCT04196413 Phase I Cyclophosphamide + Fludarabine GD2 CAR T cells GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG) Recruiting
NCT01256398 Phase II Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Mercaptopurine + Methotrexate + Vincristine Sulfate Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Active, not recruiting
NCT01853631 Phase I Anti-CD19 CAR T cells Cyclophosphamide + Fludarabine Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN) Recruiting
NCT02830724 Phase Ib/II Cyclophosphamide + Fludarabine Aldesleukin + Anti-hCD70 CAR T cells Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers Recruiting
NCT00003553 Phase II Cyclophosphamide + Fludarabine Cyclosporine Mycophenolate mofetil Methotrexate Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer Completed
NCT03287817 Phase Ib/II Pembrolizumab Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) Recruiting
NCT03049449 Phase I ATLCAR.CD30 cells Cyclophosphamide + Fludarabine T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Recruiting
NCT04088864 Phase I Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Recruiting
NCT04088890 Phase I Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Recruiting
NCT03089203 Phase I CART-PSMA-TGF-beta RDN Cyclophosphamide + Fludarabine CART-PSMA-TGF-beta RDN Cells for Castrate-Resistant Prostate Cancer Recruiting
NCT03139370 Phase I Cyclophosphamide + Fludarabine KITE-718 Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers Recruiting
NCT04103879 Phase II ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia Recruiting
NCT02995330 Phase I Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Tacrolimus + Testosterone cypionate Cyclophosphamide + Fludarabine Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer Recruiting
NCT00167180 Phase II Cyclophosphamide + Fludarabine Post Transplant Donor Lymphocyte Infusion Terminated
NCT03971799 Phase Ib/II Cyclophosphamide + Fludarabine Anti-CD33 CART cells Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia Recruiting
NCT04323657 Phase Ib/II Cyclophosphamide + Fludarabine TC-110 T-cells TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Recruiting
NCT03721068 Phase I iC9.GD2.CAR.IL-15 T-cells Cyclophosphamide + Fludarabine Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma Recruiting
NCT04314843 Phase Ib/II KTE-C19 + Lenzilumab Cyclophosphamide + Fludarabine Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19) Recruiting
NCT02905188 Phase I GLYCAR T cells Cyclophosphamide + Fludarabine Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (GLYCAR) Recruiting
NCT03913026 Phase II ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia Recruiting
NCT03441100 Phase I Cyclophosphamide + Fludarabine Aldesleukin IMA202 TCR-engineered T Cells in NSCLC and HCC Patients Recruiting
NCT03338972 Phase I Cyclophosphamide + Fludarabine Anti-BCMA CAR T Cells Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma Recruiting
NCT04377932 Phase I Cyclophosphamide + Fludarabine AGAR T cells Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors Not yet recruiting
NCT04310592 Phase I Cyclophosphamide + Fludarabine CYNK-001 Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01) Recruiting
NCT03873805 Phase I Cyclophosphamide + Fludarabine Anti-PSCA(dCH2)BBz-CAR T-cells PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer Recruiting
NCT03624036 Phase Ib/II Cyclophosphamide + Fludarabine KTE-C19 Safety and Efficacy of KTE-C19 in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia (ZUMA-8) Active, not recruiting
NCT00338377 Phase II Cyclophosphamide + Fludarabine Aldesleukin Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization Recruiting
NCT03247309 Phase I Aldesleukin + IMA201 Cyclophosphamide + Fludarabine TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) Recruiting
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting
NCT03635632 Phase I C7R-GD2.CART cells Cyclophosphamide + Fludarabine C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Recruiting
NCT03448393 Phase I Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Recruiting
NCT03241940 Phase I Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells Phase I CD19/CD22 Chimeric Antigen Receptor T Cells in Peds Recurrent/Refractory B Cell Malignancies Recruiting
NCT03704298 Phase Ib/II KTE-C19 + Utomilumab Cyclophosphamide + Fludarabine Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma (ZUMA-11) Recruiting
NCT03215810 Phase I Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Active, not recruiting
NCT04245839 Phase II JCAR017 Cyclophosphamide + Fludarabine A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL) Recruiting
NCT02356159 Phase Ib/II Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Recruiting
NCT02774291 Phase I Aldesleukin Cyclophosphamide + Fludarabine Filgrastim Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1 Recruiting
NCT04160195 Phase I Cyclophosphamide + Fludarabine Anti-CD19/CD20 CAR T cells T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Suspended
NCT03016377 Phase Ib/II Anti-CD19 CAR T cells Cyclophosphamide + Fludarabine Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL Recruiting
NCT02932956 Phase I Cyclophosphamide + Fludarabine Anti-GPC3-scFvGC33-CAR autologous T Lymphocytes Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP) Recruiting
NCT03912831 Phase I Cyclophosphamide + Fludarabine KITE-439 Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers Recruiting
NCT03938987 Phase Ib/II Cyclophosphamide + Fludarabine Anti-CD19 CAR T cells Anti-CD19, Dual Co-stimulatory (4-1BB, CD3zeta) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002) Not yet recruiting
NCT04099797 Phase I C7R-GD2.CART cells Cyclophosphamide + Fludarabine C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) Recruiting
NCT03081910 Phase I CD5 CAR T cells Cyclophosphamide + Fludarabine Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) Recruiting
NCT00881920 Phase I CAR.k.28 cells Cyclophosphamide + Fludarabine Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) Recruiting


Additional content available in CKB BOOST